In Brief: Zeneca Zoladex
Executive Summary
Zeneca Zoladex: Supplemental indication for goserelin acetate implant as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding is approved June 27. Dosing is 3.6 mg subcutaneously every 28 days into the upper abdominal wall. The implant is already indicated for endometriosis, prostatic carcinoma, and breast cancer...